Current Issue — February 2003

Smallpox plans hit one final snag: how many jabs to give?

The ACIP suggested 15 jabs for all vaccinees, but the package insert recommends three jabs for first time recipients.

Lessons learned on 9-11

Antonia Novello, MD, MPH, PhD, talks about the public health response of New York City.

Thimerosal was never present at unsafe levels in vaccines

Peginterferon plus ribavirin best therapy for HCV

The regimen is particularly beneficial for patients infected with genotype 1 virus.

Treatment decisions in co-infected patients depend on CD4 count

First ketolide drug approved by FDA

Telithromycin has been approved for the treatment of chronic bronchitis, acute bacterial sinusitis and CAP.

New advances in the prevention of cervical cancer: HPV type 16 vaccine

Persistent human papillomavirus infection of the genital tract is well known to be the precipitating factor for cervical cancer.

Do not wait to manage hepatitis C virus in HIV-positive patients

Some coinfected patients will die from liver failure before succumbing to AIDS-related opportunistic infections.

Too many viruses, too few ‘cures’ for the common cold

Physicians agree that the best way to treat the common cold is symptomatically with targeted medications.

Smallpox, the bioterror du jour: Or is it?

There are far more frightening agents than smallpox or anthrax that we have not yet considered in a systematic fashion.

Cellular transfusion therapy: A changing paradigm

This editorial first appeared in our sister publication, Hem/Onc Today. We thought you would find it interesting.